Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity

Dana Darwish, Ru Ik Chee, Samir N. Patel, Karyn Jonas, Susan Ostmo, John Campbell, Michael Chiang, R. V.Paul Chan

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Diagnosis and management of pediatric retinal conditions such as retinopathy of prematurity (ROP) have been evolving significantly with the availability of new technology and treatments. New imaging systems, telemedicine, tele-education, and anti?vascular endothelial growth factor (VEGF) intravitreal pharmacotherapy are all changing the way we diagnose and deliver care to children with pediatric retinal disease. Fluorescein angiography and optical coherence tomography have the potential to improve our diagnosis and management of disease, and with improvements in retinal imaging, telemedicine is becoming more feasible. Telemedicine, tele-education, and computer-based image analysis may overcome many of the challenges we face in providing adequate care and access for children with pediatric retinal disease. Treatment options have also expanded with the use of anti-VEGF therapy. Although the use of intravitreal anti-VEGF for ROP has been documented in the literature for more than a decade, many questions still remain about its safety in the pediatric patient population. Several ongoing prospective studies are exploring the utility of anti-VEGF agents for ROP, with attention to the optimal dose of drug, systemic safety, and our understanding of recurrence of disease. This review aims to provide an update on current diagnostic and therapeutic modalities, focusing predominantly on the role of anti-VEGF therapy, for the management of ROP and other pediatric retinal vascular diseases.

Original languageEnglish (US)
Pages (from-to)136-144
Number of pages9
JournalAsia-Pacific Journal of Ophthalmology
Volume7
Issue number3
DOIs
StatePublished - May 1 2018

Fingerprint

Retinopathy of Prematurity
Vascular Endothelial Growth Factor A
Retinal Diseases
Pediatrics
Telemedicine
Child Care
Therapeutics
Safety
Education
Retinal Vessels
Fluorescein Angiography
Optical Coherence Tomography
Disease Management
Vascular Diseases
Prospective Studies
Technology
Recurrence
Drug Therapy
Pharmaceutical Preparations
Population

Keywords

  • Anti
  • Pediatric retina
  • Retinopathy of prematurity
  • VEGF therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity. / Darwish, Dana; Chee, Ru Ik; Patel, Samir N.; Jonas, Karyn; Ostmo, Susan; Campbell, John; Chiang, Michael; Chan, R. V.Paul.

In: Asia-Pacific Journal of Ophthalmology, Vol. 7, No. 3, 01.05.2018, p. 136-144.

Research output: Contribution to journalReview article

Darwish, Dana ; Chee, Ru Ik ; Patel, Samir N. ; Jonas, Karyn ; Ostmo, Susan ; Campbell, John ; Chiang, Michael ; Chan, R. V.Paul. / Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity. In: Asia-Pacific Journal of Ophthalmology. 2018 ; Vol. 7, No. 3. pp. 136-144.
@article{2ac4a2eeb29744b4abbd5f49461057b7,
title = "Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity",
abstract = "Diagnosis and management of pediatric retinal conditions such as retinopathy of prematurity (ROP) have been evolving significantly with the availability of new technology and treatments. New imaging systems, telemedicine, tele-education, and anti?vascular endothelial growth factor (VEGF) intravitreal pharmacotherapy are all changing the way we diagnose and deliver care to children with pediatric retinal disease. Fluorescein angiography and optical coherence tomography have the potential to improve our diagnosis and management of disease, and with improvements in retinal imaging, telemedicine is becoming more feasible. Telemedicine, tele-education, and computer-based image analysis may overcome many of the challenges we face in providing adequate care and access for children with pediatric retinal disease. Treatment options have also expanded with the use of anti-VEGF therapy. Although the use of intravitreal anti-VEGF for ROP has been documented in the literature for more than a decade, many questions still remain about its safety in the pediatric patient population. Several ongoing prospective studies are exploring the utility of anti-VEGF agents for ROP, with attention to the optimal dose of drug, systemic safety, and our understanding of recurrence of disease. This review aims to provide an update on current diagnostic and therapeutic modalities, focusing predominantly on the role of anti-VEGF therapy, for the management of ROP and other pediatric retinal vascular diseases.",
keywords = "Anti, Pediatric retina, Retinopathy of prematurity, VEGF therapy",
author = "Dana Darwish and Chee, {Ru Ik} and Patel, {Samir N.} and Karyn Jonas and Susan Ostmo and John Campbell and Michael Chiang and Chan, {R. V.Paul}",
year = "2018",
month = "5",
day = "1",
doi = "10.22608/APO.201850",
language = "English (US)",
volume = "7",
pages = "136--144",
journal = "Asia-Pacific Journal of Ophthalmology",
issn = "2162-0989",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity

AU - Darwish, Dana

AU - Chee, Ru Ik

AU - Patel, Samir N.

AU - Jonas, Karyn

AU - Ostmo, Susan

AU - Campbell, John

AU - Chiang, Michael

AU - Chan, R. V.Paul

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Diagnosis and management of pediatric retinal conditions such as retinopathy of prematurity (ROP) have been evolving significantly with the availability of new technology and treatments. New imaging systems, telemedicine, tele-education, and anti?vascular endothelial growth factor (VEGF) intravitreal pharmacotherapy are all changing the way we diagnose and deliver care to children with pediatric retinal disease. Fluorescein angiography and optical coherence tomography have the potential to improve our diagnosis and management of disease, and with improvements in retinal imaging, telemedicine is becoming more feasible. Telemedicine, tele-education, and computer-based image analysis may overcome many of the challenges we face in providing adequate care and access for children with pediatric retinal disease. Treatment options have also expanded with the use of anti-VEGF therapy. Although the use of intravitreal anti-VEGF for ROP has been documented in the literature for more than a decade, many questions still remain about its safety in the pediatric patient population. Several ongoing prospective studies are exploring the utility of anti-VEGF agents for ROP, with attention to the optimal dose of drug, systemic safety, and our understanding of recurrence of disease. This review aims to provide an update on current diagnostic and therapeutic modalities, focusing predominantly on the role of anti-VEGF therapy, for the management of ROP and other pediatric retinal vascular diseases.

AB - Diagnosis and management of pediatric retinal conditions such as retinopathy of prematurity (ROP) have been evolving significantly with the availability of new technology and treatments. New imaging systems, telemedicine, tele-education, and anti?vascular endothelial growth factor (VEGF) intravitreal pharmacotherapy are all changing the way we diagnose and deliver care to children with pediatric retinal disease. Fluorescein angiography and optical coherence tomography have the potential to improve our diagnosis and management of disease, and with improvements in retinal imaging, telemedicine is becoming more feasible. Telemedicine, tele-education, and computer-based image analysis may overcome many of the challenges we face in providing adequate care and access for children with pediatric retinal disease. Treatment options have also expanded with the use of anti-VEGF therapy. Although the use of intravitreal anti-VEGF for ROP has been documented in the literature for more than a decade, many questions still remain about its safety in the pediatric patient population. Several ongoing prospective studies are exploring the utility of anti-VEGF agents for ROP, with attention to the optimal dose of drug, systemic safety, and our understanding of recurrence of disease. This review aims to provide an update on current diagnostic and therapeutic modalities, focusing predominantly on the role of anti-VEGF therapy, for the management of ROP and other pediatric retinal vascular diseases.

KW - Anti

KW - Pediatric retina

KW - Retinopathy of prematurity

KW - VEGF therapy

UR - http://www.scopus.com/inward/record.url?scp=85049195459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049195459&partnerID=8YFLogxK

U2 - 10.22608/APO.201850

DO - 10.22608/APO.201850

M3 - Review article

C2 - 29808629

AN - SCOPUS:85049195459

VL - 7

SP - 136

EP - 144

JO - Asia-Pacific Journal of Ophthalmology

JF - Asia-Pacific Journal of Ophthalmology

SN - 2162-0989

IS - 3

ER -